Chimerix surges on Jazz Pharma's $935 million buyout

Jazz Pharmaceuticals

05/03/2025 15:17

Updates

** Shares of biotech firm Chimerix CMRX.O rise 70% to a more-than-three-year high of $8.40

** Jazz Pharmaceuticals JAZZ.O will acquire Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies say

** JAZZ will pay $8.55 per Chimerix share in an all-cash deal, which is expected to close in Q2; represents around 72%  premium to its Tuesday's closing price

** CMRX has risen 320% in the past 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))